Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

RADT220 Head & Neck > Lung Cancer > Flashcards

Lung Cancer Flashcards

1
Q

What percentage of lung cancer cases do NSCLCs account for in the UK?

A

87% (most common type of lung cancer)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the 4 main histological types?

A

Squamous cell carcinoma
Adenocarcinoma
Large cell carcinoma
Mixed histologies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is a squamous cell carcinoma?

A

This type develops in the flat cells that cover the surface of the airways.

Most arise proximally in large bronchi.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the most common histological type of NSCLCs?

A

Squamous cell carcinomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is a adenocarcinoma?

A

Starts in the goblet cells that produce mucus and are found in the epithelial lining.

Tend to be slow growing and in the peripheral part of the lung - often invade pleura

Most lung cancers in people who have never smoked are adenocarcinomas.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the most common form of lung cancer?

A

Lung adenocarcinoma is the most common form of lung cancer, accounting for 30 percent of all cases overall and about 40 percent of all non-small cell lung cancer occurrences.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are large cell carcinomas?

A

10-15% of all lung cancers.

Tend to grow very quickly and spread.
More difficult to treat.

This type of lung cancer is around 20x more likely in smokers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Where do NSCLCs typically locally invade?

A

Local invasion – mediastinum, bronchial wall, lung parenchyma, pleural space, chest wall

Apical (top of lungs) tumours – brachial plexus (lower part of neck into apex of lung), upper thoracic ribs, local nerves

Hilar tumours – tumour can cause damage to phrenic of left recurrent laryngeal nerve

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Where can NSCLCs spread to lymphatic ally?

A

Lymphatic spread – mediastinal, hilar, sub-carinal, tracheobronchial and paratracheal nodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Where can NSCLCs spread to haematogenously (blood)?

A

More common in SCLC (bone, brain, liver and adrenals) – still relatively common with NSCLC aswell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What does FEV1 stand for?

A

Forced expiration volume (over 1 second)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What does DLCO stand for?

A

Diffusion rate of carbon monoxide over respiratory membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What stages can be radically managed?

A

Early and locally advanced disease (stage 1 and 2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the treatment of choice for stage 1-2?

A

Surgery (with curative intent)

Other options:
Radiotherapy
Rdaiofrequency ablation (RFA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the 3 types of resection?

A

Lobectomy
Segmentectomy
Wedge resection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is a wedge resection?

A

Removal of a small wedge shaped piece of tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is a limitation of wedge resections?

A

Higher recurrence rate of cancer returning than lobectomy due to margins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the percentage of candidates unable to have surgery?

A

40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What does Radiofrequency Ablation (RFA) do?

A

“Microwave” the tumour – ablation through heating

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What stage is SABR often used? What other factors are considered?

A

Stage 1-2
Low toxicity profile
Elderly / COPD
2 year survival 90%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What percentage of locally advanced diseased patients have radical surgery?

A

2%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What percentage of locally advanced diseased patients have radical radiotherapy?

A

14%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What percentage of locally advanced diseased patients have palliative radiotherapy?

A

44% (22% is + chemo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What percentage of locally advanced diseased patients have best supportive care?

A

39%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What so-called advance disease can be potentially resected?

A

Single staged N2 disease – and T4N0

Particularly when down-staged after induction chemotherapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

If no resection what treatment pathway is used for located advanced disease?

A

Concurrent chemo-RT gold standard

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What does SABR stand for?

A

Stereotactic Ablative Radiotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

How does SABR different conventional radiotherapy?

A

High radiation dose per fraction
Hypofractionated
Different image guidance protocols
Monitoring of tumour motion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What percentage of all reported lung cancer cases do SCLC patients represent?

A

Around 15-20% (rarer than non-small cell lung cancer)

30
Q

Does SCLC tend to spread early?

A

Yes

31
Q

Do majority of patients present with minimal or extensive disease?

A

Extensive

32
Q

What does extensive SCLC disease look like?

A

This can be thoracic disease involving more than one hemiplorax or it can be more distant metastatic spread (approximately 2/3rds of patient present with extensive disease)

33
Q

Where do malignant cells originate from?

A

Primate neuroendocrine cells (neuroendocrine-cell precursors)

34
Q

What are 3 things SCLC’s are characterised by?

A

Rapid growth – high mitotic rate

High response rates to both chemotherapy and radiotherapy

Development of treatment resistance in patients with metastatic disease

35
Q

Do patients with SCLC have a good or poor prognosis?

A

Poor

36
Q

What is the median survival time length (months)

A

15-20

37
Q

What is the percentage survival for 2 years?

A

20-40%

38
Q

What is the percentage survival for 5 years?

A

20-25%

39
Q

How many patients have T1-2 disease?

A

Less than 5%

40
Q

What percentage of T1-2 could have surgery alone?

A

5%

41
Q

What do the majority of localised disease have?

A

T3-4 node positive disease

42
Q

What treatment can the majority of localised disease have?

A

Concurrent chemo-radiotherapy (bi-daily) (CONVERT Trial) or sequential for those who are not fit enough

43
Q

What do NICE suggest to offer for treatment of limited-stage disease SCLC?

A

Offer 2 x day radiotherapy with concurrent chemotherapy
Performance Status 0 – 1,
or if present with disease that can be encompassed in a radical thoracic RT volume.
RT to commence during 1st of 2nd chemo cycle

Once daily if patient declines / unable to have twice daily RT

Patients not well enough for concurrent chemoRT, but who respond to chemo - offer sequential radical thoracic radiotherapy

Offer PCI (prophylactic cranial irradiation)– patients whose disease has not progressed on first line treatment (2019 amendment)

44
Q

What do NICE suggest to offer for treatment of extensive-stage disease SCLC?

A

Chemotherapy, or Molecular or targeted therapies

Per NICE, chemotherapy – platinum-based chemotherapy if fit enough

Assessment prior to each cycle – maximum of six cycles, dependent on response and toxicity.

Consider thoracic radiotherapy with PCI
where there has been partial or complete response to chemotherapy within thorax and at distant sites

Whole brain radiotherapy (PCI) if response to CT

Palliation – RT (symptom management)

Best supportive care (no active therapy but more of a palliative approach)

45
Q

What is the dose/fractionation for Prophylactic Cranial Irradiation (PCI) for SCLC?

A

NICE – 25Gy/10#/2 weeks (Mon-Fri)

46
Q

What does Prophylactic Cranial Irradiation (PCI) for SCLC require?

A

Whole brain
Limited stage
PS WHO 0-2
No progression after 1st line treatment

47
Q

Risks of PCI?

A

Neurocognitive decline (verbal fluency, memory)
Decreased QOL

48
Q

What percentage of lung cancer treatments does palliative EBRT make up?

A

20-30%

49
Q

What are the 2 fractionation/doses for palliative EBRT?

A

10Gy in 1# or 30Gy in 10#

50
Q

What metastases can receive RT?

A

Brain, bone and adrenal

51
Q

What are the response rate percentages for each side effect?

A

54.1% for cough,
68%for haemoptysis,
51.1% for thoracic pain,
38.3% for dyspnoea,
12% for hoarseness, and
8% for dysphagia

52
Q

What is the aim for palliative EBRT?

A

Minimal acute/late toxicity

53
Q

What is Haemoptysis?

A

Coughing up of blood from lung

54
Q

What is Dyspnoea?

A

Difficult or laboured breathing

55
Q

What is Dysphagia?

A

Painful swallowing

56
Q

What is Oesophagitis?

A

Inflammation of oesophageal lining

57
Q

What is Neutropenia?

A

Low number of white blood cells called neutrophils in your blood

58
Q

What is Anaemia?

A

A condition in which the body does not have enough healthy red blood cells

59
Q

What are some signs of RT induced toxicity? (first 24 hours)

A

Acute chest pain, rigors, sweating and fevers

60
Q

What are some signs of RT induced toxicity? (acute)

A

Lung, oesophageal and skin

61
Q

What are some signs of RT induced toxicity? (late)

A

Lung oesophageal (and cardiac)

62
Q

What is breathlessness in medical terms?

A

Dyspnoea

63
Q

What is the definition of breathlessness?

A

Breathlessness is the distressing sensation of a deficit between the body’s demand for breathing and the ability of the respiratory system to satisfy that demand.

64
Q

What are the 2 types of breathlessness?

A

Acute breathlessness: develops over minutes, hours, or days.

Chronic breathlessness: develops over weeks or months

65
Q

When can breathlessness occur pathologically?

A

Can occur with little to no exertion. (Affects 50-70% cancer patients at some point)

66
Q

After pain what is the most common symptom patients person to their GP with?

A

Breathlessness is the most common symptom for which patients seek help and relief from their doctor.

67
Q

What percentage of patients with advanced lung cancer does breathlessness affect?

A

90%

68
Q

Signs and symptoms of breathlessness

A

Difficulty catching breath
Noisy breathing
Very fast, shallow breaths
An increase in pulse rate
Wheezing
Chest pain
Skin that looks pale and slightly blue, especially around your mouth
Cold, clammy skin
Flaring nostrils when you breathe in
To use your shoulders and the muscles in your upper chest to help you breathe
Anxiety or panicky feelings

69
Q

What should be done first when a patient presents with breathlessness?

A

Find the reason for breathlessness then management (should be both clinician and patient led)

70
Q

What are the 2 management options for breathlessness?

A

Pharmaceutical and non-pharmaceutical

71
Q

What are potential causes for breathlessness?

A

Anaemia
Side effect of treatment
Heart problems
Chest infection
Pleural effusion
Tumour growth
Blood vessel blockage

RADT220 Head & Neck (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions